Mostrar el registro sencillo del ítem

dc.contributor.authorSánchez Sanz, Alicia
dc.contributor.authorPosada Ayala, María 
dc.contributor.authorSabín Muñoz, Julia
dc.contributor.authorGarcía Hernández, Ruth
dc.contributor.authorRodríguez de la Fuente, Ofir
dc.contributor.authorRomero, Julián 
dc.contributor.authorGarcía Merino, Antonio
dc.contributor.authorSánchez López, Antonio J
dc.date.accessioned2022-03-30T08:08:16Z
dc.date.available2022-03-30T08:08:16Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/10641/2908
dc.description.abstractBackground: The endocannabinoid system (ECS) consists of lipid metabolites, their receptors and the enzymes implicated in their synthesis and degradation. The ECS exerts anti-inflammatory and neuroprotective properties and its modulation has the potential of being a therapeutic target in Multiple Sclerosis (MS). Dimethyl fumarate (DMF) is an approved drug for MS, which has immunomodulatory effects although its mechanism of action is not yet fully understood. Objectives: To test if DMF could modulate the ECS in Peripheral Blood Mononuclear Cells (PBMCs) from MS patients. Methods: PBMCs from 11 Healthy Donors (HC) and 20 MS patients (at baseline and after 1 year of DMF treatment) were obtained by Ficoll density gradient centrifugation. Patients were clinically followed for 2 years; disease activity was assessed annually. The levels of the endocannabinoids 2-Arachidonoylglycerol (2-AG), Anandamide (AEA), Oleoylethanolamine (OEA) and Palmitoylethanolamine (PEA) were determined by Liquid chromatography–mass spectrometry (LC-MS), and normalized to the total amount of protein. Results: The median values (in pmol/g protein) of 2-AG and AEA were both similar between HC (361.42 for 2-AG; 63.62 for AEA) and patients at baseline (269.26 for 2-AG; 58.70 for AEA). After 1 year of treatment, no differences were found compared to baseline. However, there was a trend (p=0.07) towards an increase of 2-AG in patients that did not reach NEDA 3 on follow-up at 2 years. OEA and PEA levels were both lower at baseline (61.83 for OEA, p=0.01; 541.0 for PEA, p=0.001) compared to HC (190.35 for OEA; 1140.51 for PEA). After 1 year, PEA levels were unchanged (449.50, p=0.68), but OEA (115.39, p=0.04) increased to levels similar to those of HC. Conclusions: Our results confirm the dysregulation of the ECS in MS. Furthermore, they shed light on a new mechanism of action of DMF in MS, as it can modulate the ECS through OEAspa
dc.language.isoengspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titleEndocannabinoid system modulation in peripheral blood mononuclear cells from dimethyl fumarate-treated multiple sclerosis patients.spa
dc.typeotherspa
dc.type.hasVersionSMURspa
dc.rights.accessRightsopen accessspa
dc.description.extent110 KBspa


Ficheros en el ítem

FicherosTamañoFormatoVer
28_ECF2020_Abstract_BS_Sánchez ...109.4KbPDFVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España